First Wave BioPharma To Present at the BIO Investor Forum
15 September 2023 - 10:45PM
First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave” or the
“Company”), a clinical-stage biopharmaceutical company specializing
in the development of targeted, non-systemic therapies for
gastrointestinal (GI) diseases, today announced that James
Sapirstein, President and CEO, will make a company presentation at
the BIO Investor Forum being held October 17-18, 2023, at the
Hilton San Francisco Union Square in San Francisco.
During the conference, members of the First Wave
BioPharma management team will conduct one-on-one meetings with
registered investors and pharmaceutical companies, showcasing the
company’s business and clinical development strategy, recent
corporate achievements, and anticipated milestones.
About First Wave BioPharma,
Inc.First Wave BioPharma is a clinical-stage
biopharmaceutical company specializing in the development of
targeted, non-systemic therapies for gastrointestinal (GI)
diseases. The Company is currently advancing a therapeutic
development pipeline with multiple Phase 2 clinical stage programs
built around three proprietary technologies – Capeserod, a
selective 5-HT4 receptor partial agonist which First Wave will
pursue for gastrointestinal (GI) indications; the biologic
adrulipase, a recombinant lipase enzyme designed to enable the
digestion of fats and other nutrients in cystic fibrosis and
chronic pancreatitis patients with exocrine pancreatic
insufficiency; and niclosamide, an oral small molecule with
anti-inflammatory properties for patients with inflammatory bowel
diseases such as ulcerative colitis and Crohn’s disease. First Wave
BioPharma is headquartered in Boca Raton, Florida. For more
information visit www.firstwavebio.com.
Forward-Looking StatementThis
press release may contain certain statements relating to future
results which are forward-looking statements. It is possible that
the Company’s actual results and financial condition may differ,
possibly materially, from the anticipated results and financial
condition indicated in these forward-looking statements, depending
on factors including whether results obtained in preclinical and
nonclinical studies and clinical trials will be indicative of
results obtained in future clinical trials; whether preliminary or
interim results from a clinical trial will be indicative of the
final results of the trial; whether the Company will be able to
maintain compliance with Nasdaq’s continued listing criteria and
the effect of a delisting from Nasdaq on the market for the
Company’s securities; the size of the potential markets for the
Company’s drug candidates and its ability to service those markets;
the effects of the First Wave Bio, Inc. acquisition, the related
settlement and their effect on the Company’s business, operating
results and financial prospects; and the Company’s current and
future capital requirements and its ability to raise additional
funds to satisfy its capital needs. Additional information
concerning the Company and its business, including a discussion of
factors that could materially affect the Company’s financial
results are contained in the Company’s Annual Report on Form 10-K
for the year ended December 31, 2022 under the heading “Risk
Factors,” as well as the Company’s subsequent filings with the
Securities and Exchange Commission. All forward-looking statements
included in this press release are made only as of the date of this
press release, and we do not undertake any obligation to publicly
update or correct any forward-looking statements to reflect events
or circumstances that subsequently occur or of which we hereafter
become aware.
For more information:First Wave BioPharma,
Inc.777 Yamato Road, Suite 502Boca Raton, FL 33431Phone: (561)
589-7020info@firstwavebio.com
Media contact:Tiberend Strategic Advisors,
Inc.David Schemelia(609) 468-9325dschemelia@tiberend.com
First Wave BioPharma (NASDAQ:FWBI)
Historical Stock Chart
From Apr 2024 to May 2024
First Wave BioPharma (NASDAQ:FWBI)
Historical Stock Chart
From May 2023 to May 2024